Article citationsMore>>

Takizawa, H., Desaki, M., Ohtoshi, T., Kawasaki, S., Kohyama, T., Sato, M., Tanaka, M., Kasama, T., Kobayashi, K., Nakajima, J. and Ito, K. (1997) Erythromycin Modulates IL-8 Expression in Normal and Inflamed Human Bronchial Epithelial Cells. American Journal of Respiratory and Critical Care Medicine, 156, 266-271.
https://doi.org/10.1164/ajrccm.156.1.9612065

has been cited by the following article:

• TITLE: Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent

  AUTHORS: Eduardo Mansilla, Ricardo Rangel Martínez, Gustavo Horacio Marín, Idiberto Zotarelli Filho, Elsa Rivas, Jaime Rivas, Katherine Athayde Teixeira de Carvalho, Mohammad Reza Dayer, Alí Samadikuchaksaraei

  KEYWORDS: COVID-19, Macrolides, Clarithromycin, Single Agent, Therapy, Prophylaxis

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.11 No.6, June 18, 2020

  ABSTRACT: SARS-CoV-2 is a novel RNA coronavirus responsible of a deadly pandemic: the clinical illness COVID-19. With only one authorized drug for emergency use in critically ill patients: Remdesivir, there is not any other approved drug or vaccine yet with proven potential to overcome this infection. We exposed here many scientific evidences to support our novel idea that a macrolide, basically Clarithromycin, could be effective as a single agent for treatment and prophylaxis of COVID-19. Clarithromycin could change the history of this pandemic. It could reduce the costs of treatment and the potential adverse effects when combining more than one drug such as with Hydroxychloroquine. Clarithromycin treatment and prophylaxis as a single agent could be much more simple, safe and cheaper as giving Chloroquine or Hydroxychloroquine alone or in combination with Azithromycin as well as other therapeutic options.